Taken together, these studies suggest that targeting immunosuppressive cells in conjunction with immunotherapies that target T cells, such as anti-CTLA4 and anti-PD-L1, could be effective treatment strategies for tumor metastases. Here, CTLA4 is linked to neoplasm.